Theralase® Releases FY2022 Audited Financial Statements
26 avr. 2023 18h01 HE
|
Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
23 févr. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company
21 févr. 2023 07h35 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting
02 févr. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium
25 janv. 2023 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase ® Announces Warrant Extension
05 janv. 2023 18h17 HE
|
Theralase Technologies Inc.
TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and...
Theralase Releases Q322 Interim Financial Statements
29 nov. 2022 18h43 HE
|
Theralase Technologies Inc.
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Grants Stock Options
21 nov. 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase ® Closes Private Placement Equity Financing
17 nov. 2022 17h24 HE
|
Theralase Technologies Inc.
TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing
03 oct. 2022 07h00 HE
|
Theralase Technologies Inc.
Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”)...